Aerie Pharmaceuticals reports positive topline efficacy results of Rocket 4 phase 3 trial
Aerie Pharmaceuticals reported the successful 90-day topline efficacy results of its Rocket 4 Phase 3 clinical trial of product candidate RhopressaTM, a novel once-daily eye drop being tested for its ability to lower IOP in patients with glaucoma or ocular hypertension. October 27, 2016